Amarin Corp Plc (AMRN)

[Hamoa]

I see no scenario where the district court’s decision gets vacated. But again, I don’t think it matters. In my view, if the generics want to maximize this opportunity, they’ll just wait until the market is fully developed, or at least until the adoption of Vascepa as a CV therapy has much more momentum than it does now. That’s how they will get the benefit of a large, established customer base, created by an intensive and prolonged marketing push by Amarin for the CV indication. You really have to think of Amarin’s efforts at this point as being an undocumented joint venture of sorts between Amarin and the generics.

I would expect the generics to wait at least two years before launching. If I were them, I’d wait until Vascepa is essentially selling itself based on a successful education campaign by Amarin. That’s not the case today, but it will be eventually.